Essential Thrombocythemia and Polycythemia Vera Treatments Are Moving Toward Disease Modification

Key claim: Interferons, particularly ropeginterferon alfa-2b, are moving ET and PV treatment toward disease modification, while emerging agents like bomedemstat show promise for platelet reduction without thrombotic events.

Abstract

OncLive Peer Exchange panel discusses expanding use of interferons with FDA approval of ropeginterferon alpha-2b-njft (Besremi) for high-risk PV, and reviews promising agents in clinical development including bomedemstat for platelet reduction without thrombotic events.

Why this matters

Pending synthesis.

Source

Link